MX2016008081A - Un ensayo serologico rapido y sensible para determinar si los pacientes estan infectados con virus de herpes tipo 1 (hsv-1) y/o tipo 2 (hsv-2). - Google Patents
Un ensayo serologico rapido y sensible para determinar si los pacientes estan infectados con virus de herpes tipo 1 (hsv-1) y/o tipo 2 (hsv-2).Info
- Publication number
- MX2016008081A MX2016008081A MX2016008081A MX2016008081A MX2016008081A MX 2016008081 A MX2016008081 A MX 2016008081A MX 2016008081 A MX2016008081 A MX 2016008081A MX 2016008081 A MX2016008081 A MX 2016008081A MX 2016008081 A MX2016008081 A MX 2016008081A
- Authority
- MX
- Mexico
- Prior art keywords
- hsv
- infected
- serum
- matrix
- type
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
- G01N2333/035—Herpes simplex virus I or II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se describe un ensayo para la infección con uno o más virus de herpes simple que comprende a) dividir una muestra de suero que contiene anticuerpos en al menos tres submuestras de suero, y b) incubar separadamente cada una con una matriz física de antígenos celulares de i) células no infectadas, ii) células infectadas con HSV-1 o iii) células infectadas con HSV-2 para formar al menos tres mezclas de submuestra de suero de modo que los anticuerpos presentes en cada mezcla puedan inmunoreaccionar para formar anticuerpos fijados a matriz y al menos tres porciones de submuestra de suero preadsorbidas. Cada porción de submuestra de suero preadsorbida se incuba con una mezcla de antígenos fijados a matriz de células no afectadas por HSV-1 o HSV-2, infectadas por cada uno de HSV-1 y por HSV-2 para permitir que los anticuerpos inmunoreaccionen con los antígenos presentes para formar tres inmunoreactivos fijados a matriz. Se determina la cantidad de cada inmunoreacción, y las cantidades de reacción son de pronóstico para si el sujeto cuyo suero se sometió a prueba está infectado por uno, ambos, o ninguno de HSV-1 o HSV-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361917584P | 2013-12-18 | 2013-12-18 | |
| PCT/US2014/070915 WO2015095366A1 (en) | 2013-12-18 | 2014-12-17 | A rapid and sensitive serological assay to determine if patients are infected with herpes simplex virus type 1 (hsv-1) and/or type 2 (hsv-2) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016008081A true MX2016008081A (es) | 2017-05-12 |
Family
ID=53403646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016008081A MX2016008081A (es) | 2013-12-18 | 2014-12-17 | Un ensayo serologico rapido y sensible para determinar si los pacientes estan infectados con virus de herpes tipo 1 (hsv-1) y/o tipo 2 (hsv-2). |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10107813B2 (es) |
| EP (2) | EP3084436B1 (es) |
| JP (1) | JP6449325B2 (es) |
| CA (1) | CA2933697C (es) |
| DK (1) | DK3084436T3 (es) |
| ES (1) | ES2711177T3 (es) |
| MX (1) | MX2016008081A (es) |
| WO (1) | WO2015095366A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12098185B2 (en) | 2018-08-28 | 2024-09-24 | Pontificia Universidad Catolica De Chile | Monoclonal antibody 11B2C7 or fragment thereof, that specifically recognizes herpes simplex virus 1 and 2 |
| EP4225953A1 (en) * | 2020-10-06 | 2023-08-16 | Rational Vaccines, Inc. | Methods and kits for determining serostatus of sars-cov-2 |
| CN112945919B (zh) * | 2021-01-29 | 2023-04-28 | 上海睿钰生物科技有限公司 | 一种病毒中和抗体的检测方法、系统及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4764459A (en) * | 1984-12-28 | 1988-08-16 | The United States Of America As Represented By The Department Of Health And Human Services | Enzyme-linked immunosorbent assay (ELISA) for determining anti-bodies against herpes simplex virus (HSV) types 1 and 2 in human sera |
| US5965354A (en) | 1995-07-28 | 1999-10-12 | Chiron Corporation | Herpes simplex virus diagnostics |
| EP1725687A4 (en) * | 2004-03-05 | 2008-09-24 | Bio Rad Laboratories | SPECIFIC IMMUNOLOGICAL ASSAYS OF TYPE 2 VHS USING GLYCOPROTEIN G2 PEPTIDES |
| US7763460B2 (en) | 2005-06-24 | 2010-07-27 | Focus Diagnostics, Inc. | Methods and compositions for detecting herpes simplex virus type 2 |
-
2014
- 2014-12-17 WO PCT/US2014/070915 patent/WO2015095366A1/en active Application Filing
- 2014-12-17 US US15/104,562 patent/US10107813B2/en active Active
- 2014-12-17 EP EP14872357.0A patent/EP3084436B1/en active Active
- 2014-12-17 JP JP2016560632A patent/JP6449325B2/ja not_active Expired - Fee Related
- 2014-12-17 DK DK14872357.0T patent/DK3084436T3/en active
- 2014-12-17 CA CA2933697A patent/CA2933697C/en active Active
- 2014-12-17 EP EP18201809.3A patent/EP3505932A1/en not_active Withdrawn
- 2014-12-17 ES ES14872357T patent/ES2711177T3/es active Active
- 2014-12-17 MX MX2016008081A patent/MX2016008081A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2933697A1 (en) | 2015-06-25 |
| JP6449325B2 (ja) | 2019-01-09 |
| US10107813B2 (en) | 2018-10-23 |
| CA2933697C (en) | 2023-10-03 |
| US20160313331A1 (en) | 2016-10-27 |
| EP3084436B1 (en) | 2018-11-14 |
| ES2711177T3 (es) | 2019-04-30 |
| EP3084436A4 (en) | 2017-05-24 |
| WO2015095366A1 (en) | 2015-06-25 |
| EP3505932A1 (en) | 2019-07-03 |
| EP3084436A1 (en) | 2016-10-26 |
| DK3084436T3 (en) | 2019-02-18 |
| JP2017502314A (ja) | 2017-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Marklund et al. | Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders | |
| Long et al. | MHC II tetramers visualize human CD4+ T cell responses to Epstein–Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response | |
| Folgueira et al. | Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19 | |
| Wang et al. | Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection | |
| Gozalbo-Rovira et al. | SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients | |
| Alrubayyi et al. | Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV | |
| van Aalderen et al. | Infection history determines the differentiation state of human CD8+ T cells | |
| Qiu et al. | Safe pseudovirus-based assay for neutralization antibodies against influenza A (H7N9) virus | |
| US20170045515A1 (en) | Novel methods, bioassays, and biomarkers for hpv-related conditions | |
| Lai et al. | Increasing relative prevalence of HSV-2 infection among men with genital ulcers from a mining community in South Africa | |
| Latner et al. | Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method | |
| Zhang et al. | Epidemiological survey of human cytomegalovirus antibody levels in children from Southeastern China | |
| MX2016008081A (es) | Un ensayo serologico rapido y sensible para determinar si los pacientes estan infectados con virus de herpes tipo 1 (hsv-1) y/o tipo 2 (hsv-2). | |
| Tse et al. | Evaluation of three commercially available influenza A type-specific blocking enzyme-linked immunosorbent assays for seroepidemiological studies of influenza A virus infection in pigs | |
| Tserel et al. | Long-term elevated inflammatory protein levels in asymptomatic SARS-CoV-2 infected individuals | |
| Cassaniti et al. | Evaluation of EBV‐and HCMV‐Specific T cell responses in systemic lupus erythematosus (SLE) patients using a normalized Enzyme‐Linked immunospot (ELISPOT) assay | |
| Mazziotta et al. | Serum antibodies against the oncogenic Merkel Cell Polyomavirus detected by an innovative immunological assay with mimotopes in healthy subjects | |
| Shi et al. | Characteristics of primary Epstein–Barr virus infection disease spectrum and its reactivation in children, in Suzhou, China | |
| Huzly et al. | Performance of 14 rubella IgG immunoassays on samples with low positive or negative haemagglutination inhibition results | |
| Gardner et al. | Development of a high-throughput assay to measure the neutralization capability of anti-cytomegalovirus antibodies | |
| Chan et al. | Quantitative analysis of four rapid antigen assays for detection of pandemic H1N1 2009 compared with seasonal H1N1 and H3N2 influenza A viruses on nasopharyngeal aspirates from patients with influenza | |
| Vahed et al. | Unique type I interferon, expansion/survival cytokines, and JAK/STAT gene signatures of multifunctional herpes simplex virus-specific effector memory CD8+ TEM cells are associated with asymptomatic herpes in humans | |
| Cassaniti et al. | Seroprevalence of SARS-CoV-2 in blood donors from the Lodi Red Zone and adjacent Lodi metropolitan and suburban area | |
| Eing et al. | Evaluation of confirmatory strategies for detection of type-specific antibodies against herpes simplex virus type 2 | |
| Fang et al. | Circulating immune cell phenotypes are associated with age, sex, CMV, and smoking status in the Framingham Heart Study offspring participants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |